Anti-Viral Therapeutics Market Outlook 2026-2034: by Virus Type (HIV & AIDS, Hepatitis B, Hepatitis C, Influenza, Herpes, Respiratory Syncytial Virus, Cytomegalovirus, Other & Emerging Viruses), Route of Administration, Drug Class / Mechanism

The Anti-Viral Therapeutics Market is estimated at US$59 billion in 2026 and is projected to grow at a CAGR of 4.6% to reach US$84.5 billion by 2034.

Market Overview

The anti-viral therapeutics market includes therapeutic drugs and biologic approaches used to prevent or treat viral infections across acute, chronic, and outbreak-related disease settings. The value chain spans drug discovery, active ingredient manufacturing, formulation, clinical distribution, hospital and retail channels, and patient monitoring systems.

Major end uses include respiratory virus treatment, chronic viral disease management, outbreak response, prophylactic use, and specialist infectious disease care. At the same time, the market faces challenges linked to resistance risk, rapid pathogen evolution, regulatory demands, and variable commercial visibility outside high-incidence periods.

Market Segmentation

By Virus Type

• HIV & AIDS
• Hepatitis B
• Hepatitis C
• Influenza
• Herpes (HSV)
• Respiratory Syncytial Virus (RSV)
• Cytomegalovirus (CMV)
• Other & Emerging Viruses

By Route of Administration

• Oral
• Injectable (incl. Long-Acting)
• Topical

By Drug Class / Mechanism

• Reverse Transcriptase Inhibitors (NRTI/NNRTI)
• Protease Inhibitors
• Polymerase / Nucleoside Analog Inhibitors
• RNAi & Antisense Therapeutics
• Broad-spectrum Small-molecule Antivirals
• Capsid Inhibitors
• Others

Key Companies Analysed

• Gilead Sciences
• Merck & Co.
• Pfizer
• Roche
• Johnson & Johnson
• AbbVie
• Bristol Myers Squibb
• AstraZeneca
• Shionogi
• Novo Nordisk
• Teva Pharmaceutical Industries
• Cipla
• Dr. Reddy's Laboratories
• Aurobindo Pharma
• Sun Pharmaceutical
• Viatris
• BioCryst Pharmaceuticals
• Siga Technologies
• Enanta Pharmaceuticals
• Regeneron

Geographic Coverage

• North America - Market data and outlook to 2034
  • United States
  • Canada
  • Mexico
  
  
• Europe - Market data and outlook to 2034
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Netherlands
  • Switzerland
  • Poland
  • Sweden
  • Russia
  
  
• Asia-Pacific - Market data and outlook to 2034
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Malaysia
  • Vietnam
  
  
• Middle East and Africa - Market data and outlook to 2034
  • Saudi Arabia
  • South Africa
  • Iran
  • UAE
  • Egypt
  
  
• South and Central America - Market data and outlook to 2034
  • Brazil
  • Argentina
  • Chile
  • Peru
  
  

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

• Updated PDF report and an MS Excel workbook containing market tables and figures.
• 7-day post-sale analyst support for clarifications and in-scope supplementary data.
• Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.